Executive Summary
NASA's $109.2M delivery order to Caltech (JPL operator) affirms long-term federal commitment to space science R&D through 2028, with $90.3M already outlayed and $16.2M in unexercised options. As a non-profit FFRDC award, it carries neutral direct equity implications but signals execution risks tied to future task orders. Investors should monitor for spillover to commercial space partners amid stable NASA funding.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior General Federal Contracts digest from March 15, 2026.
Investment Signals (1)
- Sustained JPL FFRDC Operations (HIGH)▲
$109.2M obligation supports EMIT mineral dust investigation and JPL ops to 2028, with potential ceiling increase to $125.4M.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
Realization of full $109.2M obligation and $16.2M options depends on NASA issuing future task orders over 2.5-year remaining period.
Opportunities (2)
- ◆
$16.2M unexercised options could lift total value to $125.4M ceiling.
- ◆
Ongoing JPL FFRDC sponsorship enables additional NASA task orders through 2028.
Sector Themes (1)
- ◆
Large non-competed delivery order to JPL FFRDC under NAICS 541715/PSC AR22 highlights enduring federal R&D spend in earth observation and space ops.
Watch List (1)
- 👁
{"entity"=>"Caltech/JPL NASA Task Orders", "reason"=>"Dominant $109.2M contract with $90.3M outlayed exposes dependency on NASA for 2026-2028 realization.", "trigger"=>"New obligations exceeding $125.4M ceiling or outlay acceleration"}
Get daily alerts with 1 investment signals, 1 risk alerts, 2 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: General Federal Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals